mechanism of action of glp 1 agonist GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 and Anesthesia: Considerations and
Description
If Phase 3 results confirm its safety and efficacy, it could reach the market within the next 12 years
Tirzepatide (Mounjaro): Commence with 5 mg subcutaneously once weekly, with subsequent weekly titration up to 15 mg or 20 mg, depending on patient response and tolerability
The conception, design, interpretation of the results, writing, review, and approval of the submitted manuscript were made by all authors
This increases production of the stress hormone cortisol which disrupts the normal hair growth cycle
